home All News open_in_new Full Article

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

TORONTO, July 08, 2025 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialized life sciences company dedicated to the research and development of therapeutics for infectious diseases and medical countermeasures, hereby clarifies its update regarding the research study assessing Bucillamine as a potential treatment for nerve agent […]


today 14 h. ago attach_file Other

attach_file Culture
attach_file Economics
attach_file Other
attach_file Politics
attach_file Politics
attach_file Science
attach_file Economics
attach_file Economics
attach_file Other
attach_file Economics
attach_file Other
attach_file Politics
attach_file Society
attach_file Sport
attach_file Politics
attach_file Society
attach_file Sport
attach_file Other
attach_file Other
attach_file Transport


ID: 3875977760
Add Watch Country

arrow_drop_down